NRXP · NRX Pharmaceuticals, Inc. · Documents
$2.42
-0.21 (-7.98%)
At close · Oct 22
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$113.87M
Shares
43.30M
Volume · Oct 22
514.83K
Avg daily vol (3M)
874.71K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| DEF 14A | — | 2020-07-10 | 2020-07-23 | |
| PRE 14A | — | 2020-06-29 | 2020-07-23 | |
| 10-Q | — | 2020-05-15 | 2020-03-31 | |
| 10-K | — | 2020-03-30 | 2019-12-31 | |
| 8-K | — | 2020-03-24 | 2020-03-23 | |
| DEF 14A | — | 2020-03-09 | 2020-03-23 | |
| PRE 14A | — | 2020-02-27 | 2020-03-23 | |
| 8-K | — | 2020-02-14 | 2020-02-11 | |
| 8-K | — | 2020-02-11 | 2020-02-07 |
Showing 201–209 of 209 filings